1. Scrip
  2. >>Scrip Perspectives

How Humira Finally Lost The Top Spot In Drug Sales

Comirnaty Burst Onto The Scene

 
• By Eleanor Malone

AbbVie’s Humira has been the world’s best-selling drug since 2012, and if it hadn’t been for COVID-19 it would most likely have been on track to retain its position for the 10th year in row.

Covid Vaccine
COVID-19 Vaccination Has Shaken Up The Global Best-Seller Market • Source: Shutterstock

Humira (adalimumab) has finally lost its position as the bestselling drug in the world, but it took a pandemic to finally unseat it from the number one spot.

Despite sales of the anti-TNF blockbuster continuing to grow throughout the year, AbbVie Inc.’s product was overtaken by Pfizer Inc./BioNTech SE’s Comirnaty mRNA vaccine for COVID-19 in...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Scrip Perspectives

More from Scrip

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

Pipeline Watch: Eight Approvals And Nine Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

BREAKING NEWS: Sanofi Bets $9.5bn To Bag Blueprint

 
• By Kevin Grogan

Buy boosts the French major's immunology pipeline.